Humacyte, Inc. HUMA
We take great care to ensure that the data presented and summarized in this overview for Humacyte, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding HUMA
View all-
Black Rock Inc. New York, NY7.14MShares$14 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA5.6MShares$11 Million0.0% of portfolio
-
State Street Corp Boston, MA4.61MShares$9.04 Million0.0% of portfolio
-
Woodline Partners LP San Francisco, CA2.85MShares$5.58 Million0.11% of portfolio
-
Geode Capital Management, LLC Boston, MA2.14MShares$4.18 Million0.0% of portfolio
-
Center Book Partners LP Greenwich, CT1.28MShares$2.51 Million0.42% of portfolio
-
Ubs Group Ag1.12MShares$2.2 Million0.0% of portfolio
-
Two Sigma Investments, LP New York, NY919KShares$1.8 Million0.01% of portfolio
-
Israel Englander Millennium Management LLC | New York, Ny919KShares$1.8 Million0.0% of portfolio
-
Northern Trust Corp Chicago, IL901KShares$1.77 Million0.0% of portfolio
Latest Institutional Activity in HUMA
Top Purchases
Top Sells
About HUMA
Humacyte, Inc. engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs). Its investigational HAVs are designed to be easily implanted into any patient without inducing a foreign body response or leading to immune rejection. The company is developing a portfolio of HAVs, which would target the vascular repair, reconstruction, and replacement market, including vascular trauma; arteriovenous access for hemodialysis; peripheral arterial disease; and coronary artery bypass grafting, as well as developing its HAVs for pediatric heart surgery and cellular therapy delivery, including pancreatic islet cell transplantation to treat Type 1 diabetes. The company was founded in 2004 and is headquartered in Durham, North Carolina.
Insider Transactions at HUMA
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Apr 08
2025
|
Charles Bruce Green Director |
BUY
Open market or private purchase
|
Direct |
6,000
+41.67%
|
$6,000
$1.29 P/Share
|
|
Apr 08
2025
|
Kathleen Sebelius Director |
BUY
Open market or private purchase
|
Direct |
50,000
+35.41%
|
$50,000
$1.32 P/Share
|
|
Apr 07
2025
|
Michael T. Constantino Director |
BUY
Open market or private purchase
|
Direct |
16,000
+32.69%
|
$16,000
$1.26 P/Share
|
|
Dec 04
2024
|
Michael T. Constantino Director |
BUY
Open market or private purchase
|
Direct |
4,600
+21.35%
|
$18,400
$4.39 P/Share
|
|
Nov 20
2024
|
Laura E Niklason President, CEO and Director |
SELL
Open market or private sale
|
Indirect |
261,369
-13.12%
|
$1,045,476
$4.4 P/Share
|
|
Nov 20
2024
|
Brady W Dougan Director |
SELL
Open market or private sale
|
Indirect |
261,369
-13.12%
|
$1,045,476
$4.4 P/Share
|
|
Nov 19
2024
|
Brady W Dougan Director |
BUY
Open market or private purchase
|
Indirect |
1,797
+0.73%
|
$7,188
$4.44 P/Share
|
|
Nov 19
2024
|
Laura E Niklason President, CEO and Director |
BUY
Open market or private purchase
|
Direct |
1,797
+0.73%
|
$7,188
$4.44 P/Share
|
|
Nov 19
2024
|
Laura E Niklason President, CEO and Director |
SELL
Open market or private sale
|
Indirect |
427,459
-17.67%
|
$1,709,836
$4.34 P/Share
|
|
Nov 19
2024
|
Brady W Dougan Director |
SELL
Open market or private sale
|
Indirect |
427,459
-17.67%
|
$1,709,836
$4.34 P/Share
|
|
Nov 18
2024
|
Laura E Niklason President, CEO and Director |
SELL
Open market or private sale
|
Indirect |
811,172
-25.11%
|
$3,244,688
$4.44 P/Share
|
|
Nov 18
2024
|
Brady W Dougan Director |
SELL
Open market or private sale
|
Indirect |
811,172
-25.11%
|
$3,244,688
$4.44 P/Share
|
|
Sep 13
2024
|
Charles Bruce Green Director |
BUY
Exercise of conversion of derivative security
|
Direct |
1,200
+33.33%
|
$4,800
$4.09 P/Share
|
|
Sep 10
2024
|
Laura E Niklason President, CEO and Director |
SELL
Open market or private sale
|
Indirect |
288,674
-8.2%
|
$1,443,370
$5.23 P/Share
|
|
Sep 10
2024
|
Brady W Dougan Director |
SELL
Open market or private sale
|
Indirect |
288,674
-8.2%
|
$1,443,370
$5.23 P/Share
|
|
Sep 10
2024
|
Kathleen Sebelius Director |
SELL
Open market or private sale
|
Direct |
5,182
-5.95%
|
$25,910
$5.4 P/Share
|
|
Sep 10
2024
|
Kathleen Sebelius Director |
BUY
Exercise of conversion of derivative security
|
Direct |
7,000
+7.41%
|
$21,000
$3.85 P/Share
|
|
Sep 09
2024
|
Laura E Niklason President, CEO and Director |
SELL
Open market or private sale
|
Indirect |
157,704
-4.29%
|
$788,520
$5.42 P/Share
|
|
Sep 09
2024
|
Brady W Dougan Director |
SELL
Open market or private sale
|
Indirect |
157,704
-4.29%
|
$788,520
$5.42 P/Share
|
|
Aug 29
2024
|
Laura E Niklason President, CEO and Director |
BUY
Open market or private purchase
|
Direct |
1,222
+0.5%
|
$7,332
$6.54 P/Share
|
Last 12 Months Summary
| Open market or private purchase | 203K shares |
|---|---|
| Exercise of conversion of derivative security | 215K shares |
| Open market or private sale | 9.16M shares |
|---|